Self-assessment questions: Recent advances in the risk assessment and treatment of osteoporosis
The following interventions have been shown to reduce hip fracture in postmenopausal women:
Zoledronic acid
Denosumab
Alendronate
Ibandronate
Strontium ranelate
The following risk factors act independently of bone mineral density (BMD) to increase the risk of fracture:
Glucocorticoids
Aromatase inhibitor therapy
Falls
Premature menopause
Family history of hip fracture
The following statements are true:
Obesity is protective against fractures
The effect of glucocorticoids on fracture risk is dose dependent
The risk of atypical femoral fractures increases with duration of bisphosphonate therapy
Most postmenopausal women with fracture have osteoporosis (defined as BMD T-score−2.5)
The risk of osteonecrosis of the jaw is increased in patients receiving denosumab therapy
Answers to these self-assessment questions can be found on page s92.
- © 2012 Royal College of Physicians
Article Tools
Citation Manager Formats
Jump to section
Related Articles
- No related articles found.
Cited By...
- No citing articles found.